Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Ziopharm Oncology (ZIOP) to Offer Common Stock
-
Ziopharm Oncology Announces Proposed Public Offering of Common Stock
-
Ziopharm Oncology Announces Proposed Public Offering of Common Stock
-
Rockwell Medical Technologies (RMTI) Prices ~3.2M Share Offering
-
Rockwell Medical Announces Pricing of $7.5 Million Public Offering of Common Stock
-
Rockwell Medical Announces Pricing of $7.5 Million Public Offering of Common Stock
-
Cantor Fitzgerald Assumes Amicus Therapeutics (FOLD) at Overweight
-
Rockwell Medical Technologies (RMTI) Announces Proposed Public Offering of Common Stock
-
Rockwell Medical Announces Proposed Public Offering of Common Stock
-
Rockwell Medical Announces Proposed Public Offering of Common Stock
-
Arcutis Biotherapeutics (ARQT) IPO Opens at 36% Higher
-
Visa (V) PT Raised to $228 at Cantor Fitzgerald
-
Biogen (BIIB) PT Raised to $315 at Cantor Fitzgerald
-
MasterCard (MA) PT Raised to $359 at Cantor Fitzgerald
-
Cantor Fitzgerald Assumes Galmed Pharmaceuticals (GLMD) at Overweight
-
Pre-Open Stock Movers 01/29: (LEE) (LB) (GE) Higher (BHVN) (EXTR) (XLNX) Lower (more...)
-
Proteostasis Therapeutics (PTI) Thoughts After KOL Event - Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on Pfizer (PFE) Following 4Q
-
Cantor Fitzgerald Starts Selecta Biosciences (SELB) at Overweight
-
Cidara Therapeutics (CDTX) Halted on Volatility After Surge Higher
-
Aridis Pharmaceuticals (ARDS) Highlighted at Cantor Fitzgerald on Coronavirus Opportunity
-
Cantor Fitzgerald Highlights Cidara Therapeutics (CDTX) on Coronavirus Opportunity
-
Cantor Fitzgerald Starts Caledonia Mining Corporation Plc (CAL:CN) (CMCL) at Overweight
-
UPDATE: Cantor Fitzgerald Starts Provention Bio Inc. (PRVB) at Overweight; Sees Large Opportunity in Type 1 Diabetes
-
SPAC Research Releases League Tables Featuring Top SPAC Underwriters and Law Firms of 2019
-
PTC Therapeutics (PTCT) PT Raised to 'Street High' $81 at Cantor Fitzgerald
-
UPDATE: Incyte (INCY) PT Raised to $83 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on Johnson & Johnson (JNJ) Following 4Q
-
uniQure BV (QURE) PT Raised to $96 at Cantor Fitzgerald
-
Evolent Health (EVH) PT Raised to $16 at Cantor Fitzgerald
-
Makor Capital Hires Ian Epstein as New President of Its U.S. Global Macro Division
-
PlacementTracker Publishes 2019 PIPE and Private Placement Markets League Tables
-
IBM (IBM) PT Raised to $138 at Cantor Fitzgerald
-
Auryn Resources Inc (AUG:CN) (AUG) PT Lowered to Cdn$2.90 at Cantor Fitzgerald
-
Perrigo Co. (PRGO) PT Raised to $70 at Cantor Fitzgerald on Multiple Expansion
-
Freddie Mac Announces Pricing of $412 Million Multifamily Small Balance Loan Securitization
-
Orchid Island Capital Announces Estimated Fourth Quarter 2019 Results, January 2020 Monthly Dividend and December 31, 2019 RMBS Portfolio Characteristics
-
Pre-Open Stock Movers 01/16: (MNI) (SIG) (XPO) Higher (BK) (TSLA) (PPG) Lower (more...)
-
UPDATE: Cantor Fitzgerald Starts Compugen (CGEN) at Overweight
-
PolarityTE (PTE) Case Studies Reinforce Long Term Opportunity - Cantor Fitzgerald
-
Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option
-
Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option
-
Cantor Fitzgerald Reiterates Overweight Rating on PolarityTE (PTE) Following Meetings
-
HealthEquity, Inc (HQY) PT Lowered to $90 at Cantor Fitzgerald
-
Mudrick Capital Acquisition Corporation To Combine With Hycroft Mining Corporation
-
Mereo BioPharma Group (MERO) Reports Additional Positive Data from Phase 2b ASTEROID Study of Setrusumab in Adults with Osteogenesis Imperfecta; Provides Update on Regulatory Progress
-
Mereo BioPharma Announces Additional Positive Data from Phase 2b ASTEROID Study of Setrusumab in Adults with Osteogenesis Imperfecta and Provides Update on Regulatory Progress
-
Mereo BioPharma Announces Additional Positive Data from Phase 2b ASTEROID Study of Setrusumab in Adults with Osteogenesis Imperfecta and Provides Update on Regulatory Progress
-
Form 13F-HR CANTOR FITZGERALD INVEST For: Dec 31
-
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

